Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Burckin

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Nucleic Acids Research|March 10, 2001
Fully modified 2' MOE oligonucleotides redirect polyadenylationT A Vickers, J R Wyatt, T Burckin, et al.
Antisense & Nucleic Acid Drug Development|February 24, 2001
Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeysJ M Leeds, S P Henry, R Geary, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 1997
Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expressionR S Geary, J M Leeds, J Fitchett, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 22, 2001
Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in ratsR S Geary, O Khatsenko, K Bunker, et al.
Toxicologic Pathology|June 5, 1999
Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeysD K Monteith, M J Horner, N A Gillett, et al.
Journal of Pharmaceutical Sciences|February 13, 2001
Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkeyR Z Yu, R S Geary, J M Leeds, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Nucleic Acids Research|March 10, 2001
Fully modified 2' MOE oligonucleotides redirect polyadenylationT A Vickers, J R Wyatt, T Burckin, et al.
Antisense & Nucleic Acid Drug Development|February 24, 2001
Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeysJ M Leeds, S P Henry, R Geary, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 1997
Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expressionR S Geary, J M Leeds, J Fitchett, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 22, 2001
Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in ratsR S Geary, O Khatsenko, K Bunker, et al.
Toxicologic Pathology|June 5, 1999
Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeysD K Monteith, M J Horner, N A Gillett, et al.
Journal of Pharmaceutical Sciences|February 13, 2001
Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkeyR Z Yu, R S Geary, J M Leeds, et al.
Pageof 1